{"id":390444,"date":"2019-04-16T00:00:00","date_gmt":"2019-04-16T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneim0017-2019-biopharma-rheumatoid-arthritis-unmet-need-tnf-alpha-refractory-us-eu-2019\/"},"modified":"2026-04-15T23:24:02","modified_gmt":"2026-04-15T23:24:02","slug":"unneim0017-2019-biopharma-rheumatoid-arthritis-unmet-need-tnf-alpha-refractory-us-eu-2019","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneim0017-2019-biopharma-rheumatoid-arthritis-unmet-need-tnf-alpha-refractory-us-eu-2019\/","title":{"rendered":"Rheumatoid Arthritis | Unmet Need | TNF-alpha Refractory | US\/EU | 2019"},"content":{"rendered":"<p><strong>MARKET OUTLOOK<\/strong><\/p>\n<p>Rheumatoid arthritis (<abbr title=\"rheumatoid arthritis\">RA<\/abbr>) patients refractory to one or more\u00a0<abbr title=\"tumor necrosis factor\">TNF<\/abbr>-\u03b1 inhibitors are generally prescribed a non-<abbr title=\"tumor necrosis factor\">TNF<\/abbr>-targeted therapy (e.g., Bristol-Myers Squibb\u2019s Orencia, Roche\u2019s Actemra \/ RoActemra, Roche\u2019s Rituxan \/ MabThera). The recent launch of Pfizer\u2019s Xeljanz in Europe and Eli Lilly \/ Incyte\u2019s Olumiant in both the United States and Europe provides physicians additional treatment options with a convenient oral route of administration. The launch of an additional\u00a0<abbr title=\"interleukin\">IL<\/abbr>-6 inhibitor, Regeneron \/ Sanofi\u2019s Kevzara, has further expanded the treatment armamentarium. Although the\u00a0<abbr title=\"rheumatoid arthritis\">RA<\/abbr>\u00a0market offers multiple efficacious and relatively safe agents, patients refractory to\u00a0<abbr title=\"tumor necrosis factor\">TNF<\/abbr>-\u03b1 inhibitors have limited options, even with the recent entry of these newer agents; therefore, unmet need still exists for the\u00a0<abbr title=\"tumor necrosis factor-alpha inhibitor\">TNFi<\/abbr>-refractory\u00a0<abbr title=\"rheumatoid arthritis\">RA<\/abbr>\u00a0subpopulation.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What are the treatment drivers and goals for\u00a0<abbr title=\"tumor necrosis factor-alpha inhibitor\">TNFi<\/abbr>-refractory\u00a0<abbr title=\"rheumatoid arthritis\">RA<\/abbr>?<\/li>\n<li>What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?<\/li>\n<li>How do current therapies perform on key treatment drivers and goals for\u00a0<abbr title=\"tumor necrosis factor-alpha inhibitor\">TNFi<\/abbr>-refractory\u00a0<abbr title=\"rheumatoid arthritis\">RA<\/abbr>?<\/li>\n<li>What are the prevailing areas of unmet need and opportunity in\u00a0<abbr title=\"tumor necrosis factor-alpha inhibitor\">TNFi<\/abbr>-refractory\u00a0<abbr title=\"rheumatoid arthritis\">RA<\/abbr>?<\/li>\n<li>What trade-offs across different clinical attributes and price are acceptable to U.S. and European rheumatologists for a hypothetical new drug targeting\u00a0<abbr title=\"tumor necrosis factor-alpha inhibitor\">TNFi<\/abbr>-refractory\u00a0<abbr title=\"rheumatoid arthritis\">RA<\/abbr>?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Unmet Need provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.<\/p>\n<p><strong>Markets covered:<\/strong>\u00a0United States, United Kingdom, France, Germany<\/p>\n<p><strong>Primary research:\u00a0<\/strong>Survey of 60 U.S. and 31 European rheumatologists fielded in February 2019<\/p>\n<p><strong>Key companies:<\/strong>\u00a0Bristol-Myers Squibb, Roche, Pfizer, Eli Lilly, Incyte, Regeneron, Sanofi<\/p>\n<p><strong>Key drugs:<\/strong>\u00a0Rituxan \/ MabThera, Orencia, Actemra \/ RoActemra, Xeljanz, Olumiant, Kevzara<\/p>\n","protected":false},"template":"","class_list":["post-390444","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-rheumatoid-arthritis","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-931"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390444","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390444\/revisions"}],"predecessor-version":[{"id":393569,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390444\/revisions\/393569"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390444"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}